CAR-T Immunotherapy Targeting CD19- ALL

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Trial Details

NCT ID
NCT04016129
Phase
PHASE1 / PHASE2
Sponsor
Shenzhen Geno-Immune Medical Institute
Status
RECRUITING
Cancer Type
Acute Lymphoblastic (ALL) Leukemia
Interventions
  • 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Shenzhen, Guangdong, China|22.54554,114.0683
  • Shijiazhuang, Hebei, China|38.04139,114.47861

Key Eligibility Criteria

  • Age older than 6 months.
  • Native CD19 negative B cell malignancies or relapse after CD19-CAR-T immunotherapy.
  • Malignant B cells expressing one or more of the following surface molecules: CD22/CD123/CD38/CD10/CD20/TSLPR.
  • The KPS score over 80 points, and survival time is more than 1 month.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →